Differentiated NG108-15 Cells for Botulinum Neurotoxin Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting botulinum neurotoxin, such as mouse bioassays and cell-based assays, are insufficiently sensitive, necessitating the development of more practical and sensitive compositions and methods for clinical and research applications.
Innovation Solution
Differentiated NG108-15 cells are cultured in serum-free medium with retinoic acid or purmorphamine to exhibit motor neuron-like morphology and increased sensitivity to botulinum neurotoxin, allowing for enhanced detection of botulinum neurotoxin serotypes through cleavage of specific substrates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional cell lines (Neuro-2a, SK-N-SH, M17, SH-SY5Y, NT2, PC12, SiMa) are used for detection, then the assay is easier to perform, but the sensitivity is insufficient to compete with the mouse bioassay
Solution Approach 1:
The patent applies preliminary action by pre-differentiating NG108-15 cells with retinoic acid and purmorphamine before toxin exposure. This preliminary differentiation step creates cells with motor neuron-like morphology and increased sensitivity to botulinum neurotoxin, allowing the assay to achieve detection sensitivity comparable to mouse bioassay without requiring complex real-time differentiation protocols during the assay itself.
Solution Approach 2:
The patent employs parameter changes by modifying the culture conditions with specific concentrations of retinoic acid (5 μM) and purmorphamine (2.5 μM) to induce differentiation. These parameter changes transform the cell properties to enhance toxin sensitivity while maintaining assay practicality, resolving the contradiction between sensitivity and complexity.
2Measurement precision
If mouse bioassay is used for detecting botulinum neurotoxin, then the detection sensitivity is high, but the method is less practical for clinical and research applications
Solution Approach 1:
The patent applies copying by creating an in vitro model that replicates the high sensitivity of the mouse bioassay. Differentiated NG108-15 cells serve as a cellular copy of motor neurons, providing mouse-level detection sensitivity without requiring actual animal subjects. This eliminates ethical concerns, reduces cost, and simplifies the assay for routine clinical and research use while maintaining the sensitivity advantage of mouse bioassay.
3Measurement precision
If differentiated cells are used to increase sensitivity, then the detection capability improves, but the cell culture time and protocol complexity increase
Solution Approach 1:
The patent applies preliminary action by establishing a standardized differentiation protocol using retinoic acid and purmorphamine that can be performed in advance. Once cells are differentiated and stored, they maintain their sensitive state for assay use, eliminating the need for time-consuming differentiation steps during each assay run. This reduces the time loss while preserving the sensitivity benefits.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The differentiated NG108-15 cells demonstrate significantly increased sensitivity to botulinum neurotoxin, enabling more effective detection and quantification, with EC50 values as low as approximately 11 mouse LD50 units, surpassing the sensitivity of traditional cell lines.
Implementation Method 1
The LC is a zinc metalloprotease which cleaves different SNARE proteins depending on the serotype causing flaccid paralysis
Data Source
AI summary
Differentiated cholinergic cells having motor neuron-like morphology and increased sensitivity to botulinum neurotoxin are provided herein. Methods of using such differentiated cells for detecting neurotoxin are also provided.